This multifunctional construct integrated the following: (1) 177Lu radiotherapy via DOTA chelation, (2) paclitaxel chemotherapy, and (3) active targeting through a bombesin-derived peptide selective for gastrin-releasing peptide receptors (GRPr), which are frequently overexpressed in breast cancer. The gene discussed is GRPR; the disease is breast carcinoma.